MILWAUKEE, Aug. 9 /PRNewswire-FirstCall/ -- Merge eMed, a Merge Healthcare company and a leading medical imaging software and services company, today announced the release of eFilm Spanish(TM), a Spanish language version of the company’s widely used eFilm Workstation.
Currently released in version 2.1, eFilm Workstation is a downloadable software application that is deployed in thousands of facilities worldwide, allowing the viewing, manipulation and CD burning of digital medical images. To address needs among Merge Healthcare’s growing customer base, a new localized version of the product has been developed with a Spanish interface. A 30-day trial version of eFilm Spanish can be downloaded from the Merge eMed eStore at www.merge-emed.com.
The Spanish version of the software replicates eFilm Workstation 2.1, released by Merge eMed in October 2005. This version included several new features including enhanced thumbnail views and MPR, spine labeling, splitting image series and improved support for CD and DVD burning. eFilm Workstation 2.1 also added improved hanging protocol functionality for organizations using eFilm in conjunction with Merge eMed’s FUSION PACS and RIS/PACS solutions.
“Merge Healthcare is pleased to expand the usability of our eFilm Workstation by localizing the interface for our Spanish speaking customers,” says Robert White, Merge eMed president. “eFilm Workstation was the first radiology software application available via eCommerce at a price point that made the introduction of digital reading easy and accessible for radiologists in the United States, and continues today to be one of the most widely used diagnostic desktop software applications in the world. The introduction of eFilm Spanish replicates this very successful model for a new market of Spanish speaking customers.
“We will continue to leverage widespread use of eFilm Workstation software to further assist our customers with the care they provide patients and their transition from film to filmless workflow environments,” said White.
eFilm Spanish 2.1 is available for online purchase by healthcare professionals through Merge eMed’s eStore at www.merge.com, with free 30-day trials available, and through local vendors outside of the U.S. that sell eFilm Workstation through VAR agreements with Cedara Software. For information about local Value Added Resellers, contact Cedara software at 1.800.724.5970.
Merge Healthcare is a market leader in the development and delivery of medical imaging and information management software and services. Our innovative software solutions use leading-edge imaging software technologies that accelerate market delivery for our OEM customers, while our end-user solutions improve our customers’ productivity and enhance the quality of patient care they provide. For additional information, visit Merge Healthcare’s website at www.merge.com.
Merge eMed, a Merge Healthcare company, is focused on accelerating productivity for radiology departments and specialty practices, imaging centers and hospitals. By combining sophisticated RIS, PACS, advanced visualization and clinical imaging applications, Merge eMed delivers integrated end-to-end software solutions and professional services that are transforming the way our customers interact with referring physicians, manage their workflow, position their businesses in their markets and deliver imaging and information services to their customers. For additional information, visit Merge eMed’s website at www.merge-emed.com.
Cedara Software is a Merge Healthcare company focused on the development of custom engineered software applications and development tools for the medical imaging OEM and International markets. Cedara software is deployed in hospitals and clinics worldwide and is licensed by many of the world’s leading medical device and healthcare information technology companies. Cedara technologies and expertise span all the major digital imaging modalities including computed tomography (CT), magnetic resonance imaging (MRI), digital X-ray, mammography, ultrasound, echo-cardiology, angiography, nuclear medicine, positron emission tomography (PET) and fluoroscopy. Cedara medical imaging offerings are used in all aspects of clinical imaging workflow including the capture of a patient’s digital image; the archiving, communication and manipulation of digital images; sophisticated clinical applications to analyze digital images; and the use of imaging in minimally-invasive surgery. For additional information, visit Cedara’s website at www.cedara.com.
Except for the historical information herein, the matters discussed in this news release include forward-looking statements that may involve a number of risks and uncertainties. When used in this press release, the words “will,” “believes,” “intends,” “anticipates,” “expects” and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those expressed in, or implied by, the forward-looking statements based on a number of factors, including, but not limited to, challenges associated with the Company’s efforts to file its delinquent reports, its Form 10-Q for the second quarter of 2006, and all required restatements with the Securities and Exchange Commission on or before August 29, 2006, including the possible inability of the Company’s independent registered public accountants to complete their audit and review work within this timeframe, and the risk that the Company does not meet this deadline; possible decreased liquidity of the Company’s common stock and other possible adverse effects of the potential delisting from the NASDAQ National Market; the uncertainty created by, the adverse impact on relationships with customers, potential customers, suppliers and investors potentially resulting from, and other risks associated with, the changes in the Company’s senior management; costs, risks and effects of the investigation by the Audit Committee of the Board of Directors; the impact of the restatement of financial statements of the Company and other actions that may be taken or required as a result of such restatement; costs, risks and effects of legal proceedings and investigations, including the informal, non-public inquiry being conducted by the Securities and Exchange Commission and class action, derivative, and other lawsuits; risks in product and technology development, market acceptance of new products and continuing product demand, the impact of competitive products and pricing, ability to integrate acquisitions, changing economic conditions, credit and payment risks associated with end-user sales, dependence on major customers, dependence on key personnel, and other risk factors detailed in the Company’s filings with the Securities and Exchange Commission. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements contained herein to reflect future events, developments, or changed circumstances, or for any other reason.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20030430/MRGELOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comMerge eMed
CONTACT: Beth Frost-Johnson, Sr. VP of Marketing of Merge Healthcare,+1-414-977-4254, or bfrost@merge.com; or Robert White, President of MergeeMed, +1-330-655-3300, or bwhite@merge.com
Web site: http://www.merge-efilm.com//
